Medical Scientist Training Program, Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA; Department of Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, MN, USA.
Department of Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, MN, USA.
Mayo Clin Proc. 2024 Feb;99(2):241-248. doi: 10.1016/j.mayocp.2023.09.017.
To describe our early observations with sudden cardiac arrest (SCA) and sudden death (SD) in patients using vape products.
A retrospective analysis of Mayo Clinic's Windland Smith Rice Genetic Heart Rhythm Clinic and Sudden Death Genomics Laboratory was performed on all SCA survivors and decedents who presented between January 1, 2007, and December 31, 2021, to identify patients/decedents with a history of vaping. Data abstraction included patient demographics, clinical characteristics, and documented use of vape products.
Among 144 SCA survivors and 360 SD victims, there were six individuals (1%; 3 females) with unexplained SCA (n=4) or SD (n=2) that was temporally associated with vaping use with a mean age at sentinel event of 23±5 years. The SCA survivors include a 19-year-old male who was resuscitated from documented ventricular fibrillation 40 minutes after vaping and a 19-year-old male who was resuscitated from ventricular fibrillation a few hours post vaping. The first SD victim was a 19-year-old female with exercise-induced asthma who died in her sleep after vaping that evening. Autopsy results showed eosinophilic infiltrates in the lung tissue and death was attributed to bronchial asthma. The second vaping-associated death involved a 26-year-old male whose autopsy attributed the death to acute respiratory distress syndrome.
We have identified six young individuals with a history of vaping who experienced a near fatal episode or a tragic SD. Although larger cohort studies are needed to quantify the actual risk of SD, it seems prudent to sound an early warning about vaping's potential lethality.
描述我们在使用电子烟产品的患者中观察到的心脏骤停（SCA）和猝死（SD）的早期情况。
对 2007 年 1 月 1 日至 2021 年 12 月 31 日期间在梅奥诊所 Windland Smith Rice 遗传心脏节律诊所和猝死基因组学实验室就诊的所有 SCA 幸存者和死者进行了回顾性分析，以确定有使用电子烟产品史的患者/死者。数据提取包括患者人口统计学、临床特征和电子烟产品的使用情况。
在 144 例 SCA 幸存者和 360 例 SD 受害者中，有 6 名（1%；3 名女性）不明原因的 SCA（n=4）或 SD（n=2）与使用电子烟产品有关，其首发事件的平均年龄为 23±5 岁。SCA 幸存者包括一名 19 岁男性，在吸食电子烟 40 分钟后被成功复苏，另一名 19 岁男性在吸食电子烟数小时后复苏。第一位 SD 受害者是一名 19 岁女性，患有运动性哮喘，在当晚吸食电子烟后于睡眠中死亡。尸检结果显示肺部组织中有嗜酸性粒细胞浸润，死因归咎于支气管哮喘。第二个与电子烟相关的死亡事件涉及一名 26 岁男性，尸检将其死因归因于急性呼吸窘迫综合征。
我们发现了 6 名有电子烟使用史的年轻个体，他们经历了濒死发作或悲惨的 SD。尽管需要更大的队列研究来量化 SD 的实际风险，但对电子烟潜在致命性发出早期警告似乎是明智之举。
